title: Luteinizing hormone, sex steroids and extracorporeal circulation - a promising link to treat retroperitoneal sarcomas. A reconsideration of cancer treatment.
abstract: Retroperitoneal sarcomas are rare and aggressive tumors with a negative prognosis as there is currently no satisfactory treatment for them. The only proven factor that can significantly increase the otherwise poor survival of sarcoma patients is the radically of resection. However, the completeness of resection is hindered by the hypervascularized nature of sarcomas and the frequent involvement of major blood vessels. In this context, we propose to operate on retroperitoneal sarcomas only with the use of extracorporeal circulation, applying vascular clamps above and below the tumor, even with short periods of hypothermic circulatory arrest in complex cases. This technique would allow the surgeon to achieve complete tumor resections, approach large blood vessels easier and perform sofisticated vascular reconstructions with no fear of hemorrhage which is fundamental to achieve a bloodless surgical field. Also, we speculate on the etiology of retroperitoneal sarcomas that appear mostly during the period of menopause/andropause. Although both estrogens and androgens have been incriminated in inducing various cancer types, including sarcomas, an endogenous estradiol cathabolyte has been shown to have anti-tumor effects. Considering that during menopause/andropause sex steroid levels actually decrease, our second working hypothesis is that the increasing follicle-stimulating hormone (FSH) and especially luteinizing hormone (LH) levels, together with the relative estrogen/androgen imbalance, may be the triggering cause. Also, a certain level of estrogens (Methoxyestradiol) may be essential in limiting tumor development and dedifferentiation. Given that extragonadal sarcomas appear to behave as endocrine tumors, a targeted hormonal therapy, together with controlled radical resections in complex cases of tumor vascular involvement, would certainly provide a strong link to both prevention and treatment of retroperitoneal sarcomas and even of cancer in general.
authors: University of Medicine and Pharmacy Carol Davila, Bucharest, Romania. angelalazar.2008@yahoo.com
authors: Angela Madalina
authors: AM
authors: Lazar
mesh_terms: D002273:Carcinogens / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism; D005112:Extracorporeal Circulation; D005260:Female; D012739:Gonadal Steroid Hormones / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D009376:Neoplasms, Hormone-Dependent / Q000098:blood supply / Q000209:etiology / Q000378:metabolism / Q000601:surgery; D012186:Retroperitoneal Neoplasms / Q000098:blood supply / Q000209:etiology / Q000378:metabolism / Q000601:surgery*; D012509:Sarcoma / Q000098:blood supply / Q000209:etiology / Q000378:metabolism / Q000601:surgery*
chemical_list: D002273:Carcinogens; D004967:Estrogens; D012739:Gonadal Steroid Hormones; D007986:Luteinizing Hormone